Evangelos Terpos to Bone Density Conservation Agents
This is a "connection" page, showing publications Evangelos Terpos has written about Bone Density Conservation Agents.
Connection Strength
3.057
-
Controversies in the use of new bone-modifying therapies in multiple myeloma. Br J Haematol. 2021 Jun; 193(6):1034-1043.
Score: 0.726
-
Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial. Blood Adv. 2018 11 13; 2(21):2837-2847.
Score: 0.630
-
Mild leukopenia following denosumab treatment in a woman with postmenopausal osteoporosis. Endocrine. 2018 11; 62(2):487-489.
Score: 0.618
-
Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody. Cancer Treat Rev. 2019 Jun; 76:57-67.
Score: 0.163
-
The role of biphosphonates in the management of thalassemia-induced osteoporosis: a systematic review and meta-analysis. Hormones (Athens). 2018 Jun; 17(2):153-166.
Score: 0.152
-
A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America. J Med Econ. 2018 May; 21(5):525-536.
Score: 0.150
-
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018 03; 19(3):370-381.
Score: 0.149
-
Biology and treatment of myeloma related bone disease. Metabolism. 2018 03; 80:80-90.
Score: 0.147
-
Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy. Leuk Lymphoma. 2017 Oct; 58(10):2304-2309.
Score: 0.143
-
Emerging treatment approaches for myeloma-related bone disease. Expert Rev Hematol. 2017 Mar; 10(3):217-228.
Score: 0.139
-
Management of multiple myeloma bone disease: impact of treatment on renal function. Expert Rev Hematol. 2018 11; 11(11):881-888.
Score: 0.039